BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Parents who delay baby's first vaccines also likely to skip measles shots - 2Brazil approves law strengthening protective measures for female victims of gender-based violence
- 3Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- 4The most effective method to Pick A Trade-in vehicle Stage
- 5Recalled Super Greens diet supplement powder sickens 45 with salmonella
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Share your pick for the miniature headphones that you generally suggest!
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- Horses really can smell our fear, new study finds
- Intriguing Social Unesco World Legacy Locales All over The Planet
